Getinge AB (publ) (GNGBY) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Getinge AB (publ) (GNGBY), Healthcare sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 47/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 16 Mar 2026Getinge AB (publ) (GNGBY) Sağlık ve Boru Hattı Genel Bakışı
Getinge AB (publ) provides solutions for operating rooms, intensive-care units, and sterilization departments, with a global presence and focus on acute care, life science, and surgical workflows. The company's diverse product portfolio and extensive distribution network position it as a key player in the medical devices sector.
Yatırım Tezi
Getinge AB (publ) presents a notable research candidate due to its established market position in the medical devices sector and its diversified product portfolio. The company's focus on acute care, life science, and surgical workflows provides exposure to multiple growth areas within healthcare. With a P/E ratio of 22.79 and a dividend yield of 2.43%, Getinge offers a blend of value and income. Ongoing catalysts include increasing demand for healthcare solutions driven by an aging global population and advancements in medical technology. However, potential risks include currency fluctuations and competition from other medical device manufacturers.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $5.43 billion reflects Getinge's significant presence in the medical device industry.
- Profit margin of 6.5% indicates efficient operations and profitability.
- Gross margin of 45.9% demonstrates the company's ability to maintain pricing power and manage costs.
- Dividend yield of 2.43% provides an income stream for investors.
- Beta of 0.88 suggests lower volatility compared to the overall market.
Rakipler & Benzerleri
Güçlü Yönler
- Diversified product portfolio
- Global presence and distribution network
- Strong brand reputation
- Focus on innovation
Zayıflıklar
- Exposure to currency fluctuations
- Dependence on healthcare spending
- Competition from larger medical device companies
- Potential for product recalls
Katalizörler
- Ongoing: Increasing demand for healthcare solutions driven by an aging global population.
- Ongoing: Advancements in medical technology and innovation.
- Upcoming: Potential strategic acquisitions to expand product portfolio and market reach.
- Ongoing: Expansion in emerging markets with developing healthcare infrastructure.
- Ongoing: Development of integrated solutions combining hardware, software, and services.
Riskler
- Potential: Currency fluctuations impacting revenue and profitability.
- Potential: Changes in healthcare regulations and reimbursement policies.
- Ongoing: Competition from other medical device manufacturers.
- Potential: Product recalls or safety concerns.
- Potential: Economic downturns affecting healthcare spending.
Büyüme Fırsatları
- Expansion in Emerging Markets: Getinge can leverage its existing distribution network to expand its presence in emerging markets, where healthcare infrastructure is developing and demand for medical devices is increasing. This expansion can drive revenue growth and diversify the company's geographic exposure. The global medical device market is expected to reach $600 billion by 2028, offering significant opportunities for growth.
- Technological Innovation: Investing in research and development to introduce innovative products and solutions can drive growth and maintain a competitive edge. Focus areas include advanced surgical technologies, digital healthcare solutions, and personalized medicine. Continuous innovation will allow Getinge to capture market share and address evolving customer needs. Ongoing investment in R&D is crucial for long-term success.
- Strategic Acquisitions: Acquiring complementary businesses and technologies can expand Getinge's product portfolio and market reach. Strategic acquisitions can provide access to new markets, technologies, and customer segments, accelerating growth and enhancing the company's competitive position. Careful due diligence and integration are essential for successful acquisitions.
- Increased Focus on Life Science Solutions: The life science segment offers significant growth potential due to increasing demand for bioprocessing equipment and solutions. Getinge can capitalize on this trend by expanding its product offerings and strengthening its relationships with pharmaceutical and biotechnology companies. The global bioprocessing market is projected to reach $30 billion by 2027.
- Development of Integrated Solutions: Offering integrated solutions that combine hardware, software, and services can create value for customers and differentiate Getinge from competitors. Integrated solutions can improve efficiency, reduce costs, and enhance patient outcomes. This approach can also create recurring revenue streams through service contracts and software subscriptions.
Fırsatlar
- Expansion in emerging markets
- Development of integrated solutions
- Strategic acquisitions
- Increasing demand for bioprocessing solutions
Tehditler
- Changes in healthcare regulations
- Economic downturns
- Technological obsolescence
- Increased competition
Rekabet Avantajları
- Established brand reputation and long-standing relationships with customers.
- Extensive distribution network and global reach.
- Diversified product portfolio across multiple healthcare segments.
- Strong focus on innovation and research and development.
GNGBY Hakkında
Founded in 1904 and headquartered in Gothenburg, Sweden, Getinge AB (publ) has evolved into a global provider of medical technology solutions. The company operates through three primary segments: Acute Care Therapies, Life Science, and Surgical Workflows. The Acute Care Therapies segment offers products for critical care, including anesthesia machines, ventilators, and cardiovascular surgery solutions. The Life Science segment provides equipment and systems for sterile transfer, bioprocessing, and laboratory applications. The Surgical Workflows segment focuses on solutions for operating rooms, such as surgical tables, lighting systems, and sterile supply management. Getinge serves a global customer base through a network of proprietary sales companies, agents, and distributors across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Its comprehensive product portfolio and global reach solidify its position as a key player in the healthcare industry.
Ne Yaparlar
- Provides equipment for operating rooms and intensive-care units.
- Offers sterilization solutions for healthcare facilities.
- Develops and manufactures bioprocessing systems for the life science industry.
- Provides surgical workflows solutions.
- Offers acute care therapies, including anesthesia and ventilation equipment.
- Provides sterile transfer systems and closure processing systems.
İş Modeli
- Sells medical devices and equipment to hospitals, clinics, and research institutions.
- Provides service and maintenance contracts for its equipment.
- Offers software solutions for managing surgical workflows and bioprocessing operations.
- Generates revenue through a network of proprietary sales companies, agents, and distributors.
Sektör Bağlamı
Getinge AB (publ) operates in the medical devices industry, which is characterized by continuous innovation and increasing demand driven by an aging global population and rising healthcare expenditures. The industry is competitive, with key players including Abbott Laboratories (ABT), Align Technology (ALGN), and Bio-Rad Laboratories (BIO). Getinge's focus on acute care, life science, and surgical workflows positions it to capitalize on specific growth areas within the broader medical devices market.
Kilit Müşteriler
- Hospitals and clinics
- Research institutions
- Pharmaceutical and biotechnology companies
- Sterilization departments
Finansallar
Grafik & Bilgi
Getinge AB (publ) (GNGBY) hisse senedi fiyatı: Price data unavailable
Son Haberler
-
Stocks That Hit 52-Week Lows On Tuesday
· 24 Mar 2020
-
Stocks That Hit 52-Week Highs On Friday
· 10 Oca 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· 26 Kas 2019
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
GNGBY için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
GNGBY için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, GNGBY'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Yönetim: Mattias Perjos
President & CEO
Mattias Perjos serves as the President and CEO of Getinge AB (publ). Prior to joining Getinge, he held various leadership positions at other companies in the healthcare and technology sectors. His experience includes roles in sales, marketing, and general management. Perjos has a strong track record of driving growth and improving operational efficiency.
Sicil: Under Mattias Perjos' leadership, Getinge has focused on strengthening its core business, expanding its presence in key markets, and investing in innovation. He has overseen the development and launch of new products and solutions, as well as strategic acquisitions to enhance the company's competitive position. His tenure has been marked by a commitment to improving patient outcomes and delivering value to shareholders.
Getinge AB (publ) ADR Bilgileri Sponsorsuz
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. GNGBY represents shares of Getinge AB (publ), a Swedish company. As an ADR, GNGBY allows U.S. investors to invest in Getinge without the complexities of cross-border transactions. Dividends are converted to U.S. dollars before distribution.
- Ana Piyasa Sembolü: Nasdaq Stockholm, Sweden
- ADR Seviyesi: 1
- ADR Oranı: 1:1
- Ana Piyasa Sembolü: GNGB
GNGBY OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no financial disclosure, and may not meet the minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to listed companies.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for fraud or manipulation
- Lack of regulatory oversight
- Higher price volatility
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal proceedings.
- Established operating history
- Reputable management team
- Audited financial statements (if available)
- Positive news coverage or industry recognition
- Clear business model and value proposition
Yatırımcılar Getinge AB (publ) (GNGBY) Hakkında Ne Soruyor
GNGBY için değerlendirilmesi gereken temel faktörler nelerdir?
Getinge AB (publ) (GNGBY) şu anda yapay zeka skoru 47/100, düşük puanı gösteriyor. Temel güçlü yan: Diversified product portfolio. İzlenmesi gereken birincil risk: Potential: Currency fluctuations impacting revenue and profitability.. Bu bir finansal tavsiye değildir.
GNGBY MoonshotScore'u nedir?
GNGBY şu anda MoonshotScore'da 47/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
GNGBY verileri ne sıklıkla güncellenir?
GNGBY fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler GNGBY hakkında ne diyor?
GNGBY için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
GNGBY'a yatırım yapmanın riskleri nelerdir?
GNGBY için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Currency fluctuations impacting revenue and profitability.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
GNGBY'ın P/E oranı nedir?
GNGBY için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için GNGBY'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
GNGBY aşırı değerli mi, yoksa düşük değerli mi?
Getinge AB (publ) (GNGBY)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
GNGBY'ın temettü verimi nedir?
Getinge AB (publ) (GNGBY) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- The information provided is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.